Business Description
ArcticZymes Technologies ASA
ISIN : NO0010014632
Description
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Germany, Italy, France, and other countries.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 27.11 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.64 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 19.61 | |||||
| Beneish M-Score | -2.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.1 | |||||
| 3-Year EBITDA Growth Rate | -16.8 | |||||
| 3-Year EPS without NRI Growth Rate | -38.3 | |||||
| 3-Year FCF Growth Rate | -51.8 | |||||
| 3-Year Book Growth Rate | 14.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 8.17 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.88 | |||||
| 9-Day RSI | 47.27 | |||||
| 14-Day RSI | 43.48 | |||||
| 3-1 Month Momentum % | -18.65 | |||||
| 6-1 Month Momentum % | -45.79 | |||||
| 12-1 Month Momentum % | -65.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.83 | |||||
| Quick Ratio | 14.95 | |||||
| Cash Ratio | 13.66 | |||||
| Days Inventory | 745.21 | |||||
| Days Sales Outstanding | 57 | |||||
| Days Payable | 285.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.7 | |||||
| Shareholder Yield % | 0.48 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94 | |||||
| Operating Margin % | -1.37 | |||||
| Net Margin % | 4.28 | |||||
| FCF Margin % | -7.44 | |||||
| ROE % | 1.48 | |||||
| ROA % | 1.36 | |||||
| ROIC % | -0.82 | |||||
| 3-Year ROIIC % | -82.05 | |||||
| ROC (Joel Greenblatt) % | 13.53 | |||||
| ROCE % | 2.51 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 171 | |||||
| Forward PE Ratio | 79.86 | |||||
| PE Ratio without NRI | 171 | |||||
| Shiller PE Ratio | 78.94 | |||||
| PS Ratio | 6.67 | |||||
| PB Ratio | 2.19 | |||||
| Price-to-Tangible-Book | 2.45 | |||||
| Price-to-Operating-Cash-Flow | 99.85 | |||||
| EV-to-EBIT | 57.97 | |||||
| EV-to-Forward-EBIT | 26.49 | |||||
| EV-to-EBITDA | 33.21 | |||||
| EV-to-Forward-EBITDA | 77.58 | |||||
| EV-to-Revenue | 4.3 | |||||
| EV-to-Forward-Revenue | 3.78 | |||||
| EV-to-FCF | -57.82 | |||||
| Price-to-GF-Value | 0.4 | |||||
| Price-to-Projected-FCF | 1.47 | |||||
| Price-to-Median-PS-Value | 0.6 | |||||
| Price-to-Graham-Number | 4.32 | |||||
| Price-to-Net-Current-Asset-Value | 2.71 | |||||
| Price-to-Net-Cash | 3.19 | |||||
| Earnings Yield (Greenblatt) % | 1.73 | |||||
| FCF Yield % | -1.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ArcticZymes Technologies ASA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 9.366 | ||
| EPS (TTM) (€) | 0.006 | ||
| Beta | 0.47 | ||
| 3-Year Sharpe Ratio | -1.14 | ||
| 3-Year Sortino Ratio | -1.34 | ||
| Volatility % | 42.04 | ||
| 14-Day RSI | 43.48 | ||
| 14-Day ATR (€) | 0.036151 | ||
| 20-Day SMA (€) | 1.1118 | ||
| 12-1 Month Momentum % | -65.42 | ||
| 52-Week Range (€) | 1.04 - 3.74 | ||
| Shares Outstanding (Mil) | 51.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ArcticZymes Technologies ASA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ArcticZymes Technologies ASA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
ArcticZymes Technologies ASA Frequently Asked Questions
What is ArcticZymes Technologies ASA(FRA:B4V)'s stock price today?
The current price of FRA:B4V is €1.12. The 52 week high of FRA:B4V is €3.74 and 52 week low is €1.04.
When is next earnings date of ArcticZymes Technologies ASA(FRA:B4V)?
The next earnings date of ArcticZymes Technologies ASA(FRA:B4V) is 2025-02-13.
Does ArcticZymes Technologies ASA(FRA:B4V) pay dividends? If so, how much?
ArcticZymes Technologies ASA(FRA:B4V) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers